The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

Big pharmaceutical companies like Bristol Myers Squibb, Merck and Johnson & Johnson face ... further threaten the companies' ...

The S&P 500 index is up 20% year to date with several high-profile ... Pharmaceutical giant Merck (NYSE: MRK) is recognized ...

The company has previously reached settlement agreements with more than 20 other generics ... a big victory for Merck, given that Januvia remains its third best-selling product after cancer ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’s Substack by Magnus Ofstad. In this ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other low ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...